| Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study EEW Cohen, D Soulières, C Le Tourneau, J Dinis, L Licitra, MJ Ahn, ... The Lancet 393 (10167), 156-167, 2019 | 1394 | 2019 |
| Optimal treatment for recurrent/metastatic head and neck cancer JB Vermorken, P Specenier Annals of oncology 21, vii252-vii261, 2010 | 418 | 2010 |
| A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma AA Brandes, AF Carpentier, S Kesari, JM Sepulveda-Sanchez, ... Neuro-oncology 18 (8), 1146-1156, 2016 | 241 | 2016 |
| Programmed cell death-1 inhibitor–induced type 1 diabetes mellitus K Clotman, K Janssens, P Specenier, I Weets, CEM De Block The Journal of Clinical Endocrinology & Metabolism 103 (9), 3144-3154, 2018 | 221 | 2018 |
| A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy V Deschoolmeester, M Baay, P Specenier, F Lardon, JB Vermorken The oncologist 15 (7), 699-731, 2010 | 214 | 2010 |
| Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations AL Ho, I Brana, R Haddad, J Bauman, K Bible, S Oosting, DJ Wong, ... Journal of Clinical Oncology 39 (17), 1856-1864, 2021 | 137 | 2021 |
| Cetuximab: its unique place in head and neck cancer treatment P Specenier, JB Vermorken Biologics: Targets and Therapy, 77-90, 2013 | 121 | 2013 |
| Current concepts for the management of head and neck cancer: chemotherapy PM Specenier, JB Vermorken Oral oncology 45 (4-5), 409-415, 2009 | 121 | 2009 |
| Anti‐epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance C Boeckx, M Baay, A Wouters, P Specenier, JB Vermorken, M Peeters, ... The oncologist 18 (7), 850-864, 2013 | 112 | 2013 |
| Spotlight on volasertib: preclinical and clinical evaluation of a promising Plk1 inhibitor J Van den Bossche, F Lardon, V Deschoolmeester, I De Pauw, ... Medicinal research reviews 36 (4), 749-786, 2016 | 103 | 2016 |
| Overcoming cetuximab resistance in HNSCC: the role of AURKB and DUSP proteins C Boeckx, KO de Beeck, A Wouters, V Deschoolmeester, R Limame, ... Cancer letters 354 (2), 365-377, 2014 | 70 | 2014 |
| Cetuximab in the treatment of squamous cell carcinoma of the head and neck P Specenier, JB Vermorken Expert review of anticancer therapy 11 (4), 511-524, 2011 | 66 | 2011 |
| Recurrent head and neck cancer: current treatment and future prospects PM Specenier, JB Vermorken Expert review of anticancer therapy 8 (3), 375-391, 2008 | 62 | 2008 |
| Adherence to geriatric assessment-based recommendations in older patients with cancer: a multicenter prospective cohort study in Belgium C Kenis, L Decoster, J Flamaing, PR Debruyne, I De Groof, C Focan, ... Annals of Oncology 29 (9), 1987-1994, 2018 | 60 | 2018 |
| Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma P Specenier, JB Vermorken Expert Review of Anticancer Therapy 18 (9), 901-915, 2018 | 57 | 2018 |
| Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment response C Boeckx, C Weyn, I Vanden Bempt, V Deschoolmeester, A Wouters, ... BMC research notes 7, 1-8, 2014 | 56 | 2014 |
| Neoadjuvant chemotherapy in head and neck cancer: should it be revisited? PM Specenier, JB Vermorken Cancer letters 256 (2), 166-177, 2007 | 54 | 2007 |
| A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial R Galot, C Le Tourneau, E Saada-Bouzid, A Daste, C Even, P Debruyne, ... European Journal of Cancer 158, 17-26, 2021 | 42 | 2021 |
| A Belgian survey on geriatric assessment in oncology focusing on large-scale implementation and related barriers and facilitators C Kenis, P Heeren, L Decoster, K Van Puyvelde, G Conings, F Cornelis, ... The Journal of nutrition, health and aging 20 (1), 60-70, 2016 | 40 | 2016 |
| Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5‐fluorouracil or carboplatin/paclitaxel for first‐line treatment of recurrent/metastatic squamous cell carcinoma of … A Jimeno, JP Machiels, L Wirth, P Specenier, TY Seiwert, F Mardjuadi, ... Cancer 122 (24), 3803-3811, 2016 | 38 | 2016 |
